Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Histamine H3 receptor (H3R) antagonists/inverse agonists possess potential to treat diverse disease states of the central nervous system (CNS). Cognitive dysfunction and motor impairments are the hallmark of multifarious neurodegenerative and/or psychiatric disorders. This review presents the various neurobiological/neurochemical evidences available so far following H3R antagonists in the pathophysiology of Alzheimer's disease (AD), attention-deficit hyperactivity disorder (ADHD), schizophrenia, and drug abuse each of which is accompanied by deficits of some aspects of cognitive and/or motor functions. Whether the H3R inverse agonism modulates the neurochemical basis underlying the disease condition or affects only the cognitive/motor component of the disease process is discussed with the aim to provide a rationale for their use in diverse disease states that are interlinked and are accompanied by some common motor, cognitive and attentional deficits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627 · cited 1×
“However, the progressive cholinergic cell loss in basal forebrain linked with AD (Whitehouse et al., 1982) probably confines the therapeutic efficacy of drugs to be reliant on endogenous ACh synthesis and doesn’t provide disease-modifying efficacy in addition to symptomatic improvement.”
BackgroundIs there a common molecular pathway for addiction?
Nestler, E. J. (2005) · Nature Neuroscience · doi:10.1038/nn1578 · Cited by 1,388 · cited 2×
“One common mechanism for addiction caused by various drugs of abuse is thought to be the activation of brain’s reward circuitry which mainly involves mesolimbic dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and their targets in limbic forebrain especially NAc (Nestler, 2005).”
BackgroundThe GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191
The role of histamine and the tuberomamillary nucleus in the nervous system
Haas, H., & Panula, P. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1034 · Cited by 929 · cited 2×
“, 2011), and the neurotransmitter modulates cognition processes via both human H1 and H2 receptors or via cholinergic and GABAergic interneurons either directly via excitation of neocortical pyramidal neurons and thalamic relay neurons or indirectly via excitation of ascending cholinergic neurons (Bacciottini et al.,…”
BackgroundStaging of Alzheimer-Related Cortical Destruction
Braak, H., Braak, E., & Bohl, J. (2008) · European Neurology · doi:10.1159/000116984 · Cited by 836 · cited 1×
“Braak et al. (1993) suggested that during the course of AD, diminished histamine production is paralleled by build up of NFT in the TMN in the early stages.”
BackgroundGoodman, A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.030 · Cited by 413
Cortese, S. (2012) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2012.01.009 · Cited by 335
The neurobiology of attention deficit/hyperactivity disorder
Curatolo, P., Paloscia, C., D'Agati, E., Moavero, R., & Pasini, A. (2009) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2008.06.003 · Cited by 136
Alterations in the histaminergic system in Alzheimer's disease: a postmortem study
Shan, L., Bossers, K., Unmehopa, U., Bao, A.-M., & Swaab, D. F. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.026 · Cited by 84 · cited 2×
“…patients as revealed by receptor binding data (Medhurst et al., 2007, 2009) or increased expression of H3R mRNA (in brains of female AD patients) is evidenced by PCR studies (Shan et al., 2012), signifying that they constitute an adequate target to improve the cognitive disorders encountered in AD.”
Background
Cited by
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
Stanciu, G. D., Luca, A., Rusu, R. N., Bild, V., Beschea Chiriac, S. I., Solcan, C., Bild, W., & Ababei, D. C. (2019) · Biomolecules · doi:10.3390/biom10010040 · Cited by 297
Alzheimer's disease failed clinical trials
Asher, S., & Priefer, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120861 · Cited by 124
Abdi Dezfouli, R., Akbariforoud, S., & Esmaeilidezfouli, E. (2024) · Middle East Current Psychiatry · doi:10.1186/s43045-024-00405-w · Cited by 4
“Another study revealed that adults with ADHD exhibiting cognitive impairment symptoms were at a higher risk of developing Alzheimer’s disease compared to those without such symptoms [104].”
Background
Metadata
- Authors
- Vohora, D., & Bhowmik, M.
- Venue
- Frontiers in Systems Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2012
- Volume
- 6
- Pages
- 72-72
- ISSN
- 1662-5137 (ISSN-L)
- OpenAlex
- W1979834293
- Cited by
- 75
- References
- 9
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse. https://app.cochat.ai/papers/10.3389/fnsys.2012.00072
- The paper
- Vohora, D., & Bhowmik, M. (2012). Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse. Frontiers in Systems Neuroscience. https://doi.org/10.3389/fnsys.2012.00072
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.